[go: up one dir, main page]

AR107916A1 - ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS - Google Patents

ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS

Info

Publication number
AR107916A1
AR107916A1 ARP170100674A ARP170100674A AR107916A1 AR 107916 A1 AR107916 A1 AR 107916A1 AR P170100674 A ARP170100674 A AR P170100674A AR P170100674 A ARP170100674 A AR P170100674A AR 107916 A1 AR107916 A1 AR 107916A1
Authority
AR
Argentina
Prior art keywords
tnfa
necrosis factor
tumor necrosis
functional fragments
same
Prior art date
Application number
ARP170100674A
Other languages
English (en)
Inventor
Esther Maria Furrer
Sebastian Meyer
Tea Gunde
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of AR107916A1 publication Critical patent/AR107916A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a moléculas de anticuerpos y a sus fragmentos funcionales, capaces de unirse al factor a de necrosis tumoral (TNFa), a procesos para su producción, y a sus usos terapéuticos.
ARP170100674A 2016-03-17 2017-03-17 ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS AR107916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16160918.5A EP3219727B1 (en) 2016-03-17 2016-03-17 Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number Publication Date
AR107916A1 true AR107916A1 (es) 2018-06-28

Family

ID=55542579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100674A AR107916A1 (es) 2016-03-17 2017-03-17 ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS

Country Status (27)

Country Link
US (1) US10975143B2 (es)
EP (2) EP3219727B1 (es)
JP (1) JP7126485B2 (es)
KR (1) KR102474765B1 (es)
CN (1) CN109071651B (es)
AR (1) AR107916A1 (es)
BR (1) BR112018067713A2 (es)
CA (1) CA3011786A1 (es)
CY (1) CY1123781T1 (es)
DK (1) DK3219727T3 (es)
EA (1) EA201892097A1 (es)
ES (1) ES2843974T3 (es)
HR (1) HRP20210120T1 (es)
HU (1) HUE052869T2 (es)
IL (1) IL261140B2 (es)
JO (1) JOP20170063B1 (es)
LT (1) LT3219727T (es)
MA (1) MA43738A (es)
PL (1) PL3219727T3 (es)
PT (1) PT3219727T (es)
RS (1) RS61412B1 (es)
SG (1) SG11202000029PA (es)
SI (1) SI3219727T1 (es)
SM (1) SMT202000703T1 (es)
TW (1) TWI758280B (es)
UY (1) UY37158A (es)
WO (1) WO2017158097A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
CN118873822A (zh) 2016-12-14 2024-11-01 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
CA3055256A1 (en) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020051275A1 (en) * 2018-09-05 2020-03-12 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
CA3120619A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2000029584A1 (en) 1998-11-18 2000-05-25 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
KR101834797B1 (ko) 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
RU2522245C2 (ru) 2008-07-10 2014-07-10 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способы и композиции для улучшенной доставки макромолекул
BR112012025568A2 (pt) * 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
EP2593476A2 (en) * 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
WO2012041018A1 (zh) * 2010-09-30 2012-04-05 成都康弘生物科技有限公司 抗TNFα的人源化抗体及其抗原结合片段Fab和用途
CA2816291C (en) * 2010-10-29 2016-08-23 Daiichi Sankyo Company, Limited Anti-dr5 antibody
WO2014089111A1 (en) * 2012-12-05 2014-06-12 Novartis Ag Compositions and methods for antibodies targeting epo
SG11201509899PA (en) 2013-06-26 2016-01-28 Numab Ag Novel antibody frameworks
US9416197B2 (en) * 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
WO2015089283A1 (en) * 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
KR20160142849A (ko) * 2014-03-26 2016-12-13 셀 메디카 스위처란트 아게 Tnf 알파에 대한 결합 구성원
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты

Also Published As

Publication number Publication date
CY1123781T1 (el) 2022-05-27
TW201739765A (zh) 2017-11-16
BR112018067713A2 (pt) 2019-01-08
WO2017158097A1 (en) 2017-09-21
ES2843974T3 (es) 2021-07-21
IL261140B2 (en) 2023-04-01
MA43738A (fr) 2018-11-28
EP3430045B1 (en) 2023-08-23
CA3011786A1 (en) 2017-09-21
SG11202000029PA (en) 2020-02-27
LT3219727T (lt) 2021-02-10
HRP20210120T1 (hr) 2021-03-05
SI3219727T1 (sl) 2021-04-30
EP3219727B1 (en) 2020-12-16
US20200299375A1 (en) 2020-09-24
US10975143B2 (en) 2021-04-13
CN109071651B (zh) 2022-08-30
PL3219727T3 (pl) 2021-05-17
JOP20170063B1 (ar) 2021-08-17
IL261140A (en) 2018-10-31
JP7126485B2 (ja) 2022-08-26
DK3219727T3 (da) 2021-01-04
EA201892097A1 (ru) 2019-02-28
EP3430045A1 (en) 2019-01-23
HUE052869T2 (hu) 2021-05-28
RS61412B1 (sr) 2021-03-31
PT3219727T (pt) 2021-01-21
KR20180118671A (ko) 2018-10-31
KR102474765B1 (ko) 2022-12-06
JP2019512269A (ja) 2019-05-16
TWI758280B (zh) 2022-03-21
EP3219727A1 (en) 2017-09-20
IL261140B (en) 2022-12-01
CN109071651A (zh) 2018-12-21
SMT202000703T1 (it) 2021-01-05
UY37158A (es) 2017-10-31

Similar Documents

Publication Publication Date Title
AR107916A1 (es) ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS
AR107917A1 (es) ANTICUERPOS CONTRA EL FACTOR a DE NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
UY35399A (es) Conjugados de fármacos con anticuerpos
CL2015002246A1 (es) Conjugados de anticuerpos drogas.
UY36154A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
UY36687A (es) Anticuerpos contra ox40 y sus usos
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
BR112018017276A2 (pt) anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
BR112018017165A2 (pt) anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
BR112018073384A2 (pt) polinucleotídeos moduladores